Liver function and survival improve after treatment with Viekirax + Exviera

Liver function and survival improve after treatment with Viekirax + Exviera
"The percent of genotype 1 HCV patients developing liver morbidity (compensated cirrhosis, decompensated cirrhosis, HCC, liver transplantation and liver death) was significantly reduced with 3D +/- ribavirin treatment compared to HCV patients who were …
Read more here.

Updated Guidance for Use of Hepatitis C Drugs
Quantitative HCV RNA testing is recommended prior to the initiation of antiviral therapy to document the baseline level of viremia (i.e., the baseline viral load). Testing for the HCV genotype is recommended to guide the selection of the most …
Read more here.

Hepatitis B and C co-infection linked to worse liver fibrosis than hepatitis B
Rates of hepatitis delta (HDV) infection were similar for hepatitis B patients with and without HCV, and HCV genotype distribution was the same for hepatitis C patients with and without HBV. People with HBV and HCV co-infection and those with HCV alone …
Read more here.

Characterization of Full-Length Genomes of Hepatitis B Virus Quasispecies in
A triple mutation (A1762T/G1764A/G1896A) was observed more frequently in genotype C than in genotype B. The MFI indicated that specific peptides of the studied regions had more frequent mutations in ACLF. Furthermore, several amino acid variations, …
Read more here.

New HCV Drugs Cost-effective for Some With Genotypes 2 and 3
Researchers assessing the cost-effectiveness of expensive new interferon-free hepatitis C drugs looked beyond the most common group, genotype 1, and found the drugs are cost-effective for some patients with genotypes 2 and 3, budgets permitting.
Read more here.

FDA Grants Breakthrough Therapy Designation for Genotype 1 Hepatitis C
The daclatasvir-sofosbuvir regimen for the treatment of genotype 1 hepatitis C patients was granted amended Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA). In the beginning of 2015, the FDA had planned to remove …
Read more here.

The Challenge of Genotype 3
For many clinicians, genotype 3 now presents the greatest challenge in the treatment and management of patients with hepatitis C virus. In a recent paper published in the Journal of Viral Hepatology, HCV Next Editorial Board member Nezam H. Afdhal, MD, …
Read more here.

Burman's Specialty Pharmacy study shows hepatitis C cure possible while
According to the study – reported in 'Specialty Pharmacy News' June edition – among 1,093 genotype 1a and 1b patients who have completed treatment over the last six months, 385, or 35%, had a clinical profile that qualified them for eight weeks …
Read more here.


Leave a Reply